US Stock MarketDetailed Quotes
ADXS Ayala Pharmaceuticals
- 0.665000
- +0.110000+19.82%
15min DelayClose Apr 29 16:00 ET
28.35MMarket Cap-264P/E (TTM)
0.665000High0.555000Low1.78KVolume0.555000Open0.555000Pre Close1.16KTurnover0.02%Turnover RatioLossP/E (Static)42.63MShares1.95000052wk High-4.55P/B6.39MFloat Cap0.50000052wk Low--Dividend TTM9.61MShs Float187499.985000Historical High--Div YieldTTM19.82%Amplitude0.500000Historical Low0.651000Avg Price1Lot Size
Ayala Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 14.56%-29.49M | 11.83%-7.2M | 25.22%-6.98M | 10.03%-34.51M | -4.83%-8.17M | 0.34%-9.34M | 39.18%-7.02M | -3.47%-9.98M | -39.27%-38.36M | -11.75%-7.79M |
| Net income from continuing operations | -26.46%-48.07M | -152.62%-24.67M | 27.94%-7.34M | 5.57%-38.01M | 2.81%-9.77M | -3.97%-10.19M | 25.89%-8.03M | -4.80%-10.03M | -33.53%-40.25M | -6.93%-10.05M |
| Operating gains losses | --5.85M | --5.97M | ---17K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 127.78%369K | 451.22%226K | 10.00%44K | -3.57%162K | 46.43%41K | -13.04%40K | 172.86%51K | -81.71%30K | -7.69%168K | -36.36%28K |
| Other non cash items | --9.87M | --9.8M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 3.01%1.13M | 18.00%1.45M | -40.82%174K | 214.99%1.1M | -18.62%1.23M | 281.48%294K | 117.03%205K | 42.57%-630K | -211.71%-954K | -20.87%1.51M |
| -Change in receivables | 200.00%234K | --0 | --0 | -134.36%-234K | -128.15%-105K | -76.08%133K | 149.47%376K | -224.61%-638K | 421.23%681K | 505.43%373K |
| -Change in prepaid assets | -166.80%-1.49M | -91.21%99K | -94.27%45K | 290.12%2.23M | 202.69%1.13M | 154.51%785K | -4,494.44%-827K | 1,404.55%1.15M | -14.09%-1.17M | -57.97%372K |
| -Change in payables and accrued expense | 498.01%2.6M | 1,215.89%1.41M | 126.65%145K | -41.65%-653K | -85.99%107K | -175.35%-544K | 316.90%924K | 25.05%-1.14M | -122.00%-461K | -40.17%764K |
| -Change in other current assets | 396.18%1.43M | 1,626.47%1.17M | 140.82%118K | --288K | --68K | --49K | ---- | ---- | ---- | ---- |
| -Change in other current liabilities | -206.16%-1.64M | -3,950.00%-1.23M | -3.88%-134K | ---536K | --32K | ---129K | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 14.56%-29.49M | 11.83%-7.2M | 25.22%-6.98M | 10.03%-34.51M | -4.83%-8.17M | 0.34%-9.34M | 39.18%-7.02M | -3.47%-9.98M | -39.27%-38.36M | -11.75%-7.79M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 297,400.00%5.95M | 60.00%-2K | -102.76%-5K | 0 | ||||||
| Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 88.89%-5K | --0 |
| Net business purchase and sale | --1.91M | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Net other investing changes | 201,950.00%4.04M | ---- | ---- | ---2K | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 297,400.00%5.95M | ---- | ---- | 60.00%-2K | ---- | ---- | ---- | --0 | -102.76%-5K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 25,343.69%26M | 750.41%4M | 327.35%2M | -100.31%-103K | -115.58%-615K | -91.93%468K | 0 | -99.81%44K | -37.02%33.33M | 1,447.84%3.95M |
| Net issuance payments of debt | --6M | --4M | ---- | --0 | --0 | ---- | ---- | ---- | ---- | ---- |
| Net common stock issuance | 19,518.45%20M | --0 | --0 | -100.31%-103K | -115.77%-615K | -91.90%468K | --0 | -99.81%44K | -36.88%33.23M | 30,100.00%3.9M |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | -64.06%101K | -82.46%47K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 25,343.69%26M | 750.41%4M | 327.35%2M | -100.31%-103K | -115.58%-615K | -91.93%468K | --0 | -99.81%44K | -37.02%33.33M | 1,447.84%3.95M |
| Net cash flow | ||||||||||
| Beginning cash position | -92.70%2.72M | -79.01%2.42M | -63.77%7.38M | -11.87%37.34M | -72.05%11.51M | -54.47%20.38M | -51.39%27.4M | -11.87%37.34M | 152.08%42.37M | -16.07%41.18M |
| Current changes in cash | 107.11%2.46M | 131.24%2.74M | 43.83%-4.98M | -588.03%-34.62M | -128.48%-8.79M | -148.44%-8.87M | 39.51%-7.02M | -171.04%-9.94M | -119.68%-5.03M | 42.60%-3.85M |
| Effect of exchange rate changes | --26K | --52K | --15K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| End cash Position | 91.34%5.21M | 91.34%5.21M | -79.01%2.42M | -92.70%2.72M | -92.70%2.72M | -72.05%11.51M | -54.47%20.38M | -51.39%27.4M | -11.87%37.34M | -11.87%37.34M |
| Free cash flow | 14.56%-29.49M | 11.83%-7.2M | 25.22%-6.98M | 10.04%-34.51M | -4.83%-8.17M | 0.36%-9.34M | 39.20%-7.02M | -3.47%-9.98M | -39.06%-38.36M | -12.21%-7.79M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg